Investor Relations 2021

Key Business Performance TruximaⓇ ✓ Maintaining the highest market share(41%) in EU5 comparing to the original (27%) and competitor(31%) ✓ Expecting the gradual expansion of market share while retaining high profitability in the US Market share of TruximaⓇ in Europe 100% 90% 80% 70% 60% 50% 40% 30% 18% 20% Market share of TruximaⓇ in the US 100% 90% 80% 70% 60% 25% 38% 39% 36% 37% 36% 20% 31% 15% 10% 6% 14% 22% 20% 20% 5% 1% 10% 2% 0% 0% 19.4Q 20.1Q 2Q 3Q 4Q 21.1Q 17.2Q 4Q 18.2Q 4Q 19.2Q 4Q 20.2Q 4Q TruximaⓇ Rituxan® A Biosimilar TruximaⓇ RixutanⓇ B Biosimilar Note: market share is based on volume Source: IQVIA Note: market share is based on unit Source: Symphony Health Investor Relations 2021 9

View entire presentation